The aim of the study was to quantify elvitegravir (EVG) concentrations in the semen of HIV-1-infected men receiving antiretroviral therapy (ART) consisting of an elvitegravir/cobicistat/ emtricitabine/tenofovir (EVG/COBI/FTC/TDF) single-tablet regimen.
Introduction
Sexual transmission is the most common route of HIV acquisition [1] . Early treatment of people living with HIV (PLWH) with combined antiretroviral therapy (ART) reduces the risk of HIV transmission to their sexual partners [2] . However, the male genital tract is an HIV reservoir [3] where viral replication may persist, even in patients with suppressed plasma HIV RNA, and contribute to HIV shedding in seminal fluid [4] . The ability of antiretroviral (ARV) drugs to penetrate into the male genital tract is a key factor for achieving and maintaining seminal HIV suppression and preventing sexual transmission of the virus [5] [6] [7] .
Elvitegravir (EVG) is an integrase transfer inhibitor that is given once daily in combination with a Cytochrome P450 3A (CYP3A) enzymes inhibitor as a pharmacological booster. EVG is available in co-formulation with the CYP3A enzyme-based pharmacokinetic enhancer cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) as a single-tablet regimen [8] . In randomized clinical trials, EVG/COBI/FTC/TDF has demonstrated high efficacy-comparable to that of efavirenz plus TDF/ FTC and ritonavir-boosted atazanavir plus TDF/FTC in treatment-na€ ıve HIV-1-infected patients-while exhibiting a favourable toxicity profile [9, 10] , and is recommended as initial therapy in current HIV-1 treatment guidelines [11, 12] . In addition, EVG/COBI/FTC/TDF is efficacious and well tolerated as a switching strategy in PLWH receiving a ritonavir-boosted protease inhibitor (PI/r) or a nonnucleoside reverse transcriptase inhibitor (NNRTI) in the absence of previously developed or acquired drug resistance [13, 14] , which makes it a good option for ART simplification or toxicity-driven switching.
There are no published data on EVG concentrations in semen. As this information is of interest to determine the ability of this ARV to contribute to preventing sexual transmission of HIV, the aim of this study was to assess EVG concentrations in seminal plasma of men living with HIV (MLWH) receiving EVG/COBI/FTC/TDF.
Methods

Study design and population
This was a phase IV, cross-sectional, single-arm, openlabel, pilot study, including MLWH who switched to EVG 150 mg plus COBI 150 mg, FTC 200 mg, and TDF 300 mg, co-formulated as a single-tablet regimen. Participants were recruited at the HIV out-patient clinic of Bellvitge University Hospital (Barcelona, Spain) between July and August 2014. Eligible participants were male adults (≥ 18 years old) with chronic HIV-1 infection, receiving a stable ART regimen consisting of TDF/FTC or abacavir/ lamivudine (ABC/3TC) plus one NNRTI or one ritonavirboosted PI for at least six consecutive months and showing plasma HIV-1 RNA suppression (< 40 copies/mL) for 6 months or longer. The exclusion criteria were evidence of primary viral resistance to the study drugs, chronic hepatitis B virus (HBV) infection, moderate or severe hepatic impairment, estimated glomerular filtration rate <70 mL/min, active opportunistic infections, or active malignancies.
The study protocol was approved by the ethical review committee of Bellvitge University Hospital in accordance with the principles of the 2008 Declaration of Helsinki and the Spanish regulatory authorities. Written informed consent was obtained from all participants before any study procedures were performed. This study was registered at the EU Clinical Trials Registry (EudraCT 2013-005116-10).
Procedures and laboratory methods
Paired blood and semen samples were obtained 4 weeks after switching to EVG/COBI/FTC/TDF. Semen samples were collected by self-masturbation and participants were recommended to abstain from sexual activity at least 72 h before the visit. In addition, CD4 lymphocyte counts and haematology and chemistry (liver function, renal function, electrolyte and lipid) tests were performed at baseline and at the study visit.
Participants were requested to take TDF/FTC/EVG/COBI every day at the same time in the morning. After confirming that the last dose of TDF/FTC/EVG/COBI was taken correctly and at the right time, blood and semen samples were obtained at the end of the dosing interval (24 h post-dose AE 1 h and before the next dose) and were processed within 2 h after collection. Specimens were centrifuged to obtain blood plasma (BP) and seminal plasma (SP). HIV-1 RNA levels were measured in BP and SP using a real-time polymerase chain reaction (PCR) assay (Abbott RealTime HIV-1, Abbott Molecular Inc., Des Plaines, IL, USA) with a quantification limit of 40 copies/mL. BP and SP samples destined to be used to determine EVG concentrations were transferred to microvials and frozen at À80°C until analysis. EVG concentrations were measured at the University of North Carolina Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, using a validated liquid chromatographyÀtandem mass spectrometry (LC-MS/MS) method. Briefly, EVG was extracted from calibration standards, quality control samples, and study samples using protein precipitation. Thirty microlitres of plasma and semen samples were mixed with 300 lL of methanol containing the stable, isotopically labelled internal standard elvitegravir-d 6 (EVG-IS). Following vortex and centrifugation steps, the supernatant was diluted with water prior to LC-MS/MS analysis. Chromatographic separation of EVG and EVG-IS from matrix components was achieved using reverse-phase chromatography on a Waters Atlantis T3 (Waters Corp., Milford, MA, USA) (50 9 2.1 mm; 3 lm) analytical column prior to detection on an AB Sciex API-5000 triple quadrupole mass spectrometer (AB Sciex, Foster City, CA). Results were generated with the Sciex ANALYST software using 1/ concentration 2 -weighted linear regression of the analyte:
internal standard peak area ratio versus concentration. The calibration range for EVG in BP and SP was 10 to 10 000 ng/mL. Calibration standards and quality control (QC) samples were within 15% of their nominal value.
Statistical methods
Quantitative variables are reported as mean and standard deviation (SD) and median and range. Qualitative variables are expressed as number and percentage. The Spearman test was used to determine associations between variables, and the coefficient of variation was used to assess within-group variability. SPSS software for Windows, version 18.0 (SPSS, Chicago, IL) was used for the statistical analysis.
Results
Ten MLWH were included and completed the study. The median age was 40 years (range 24-47), the median time on ART was 50 months (range 10-186), the median time with plasma HIV-1 RNA <40 copies/mL was 37 months (range 7-113) and the median CD4+ T cell count 737 cells/lL (range 190-1122). No patient was co-infected by HCV and only 1 had previously presented an AIDS defining disease. The last ART regimen before switching to EVG/COBI/FTC/TDF was TDF/FTC plus darunavir/ritonavir, ABC/3TC plus darunavir/ritonavir and TDF/FTC plus etravirine in 5, 4 and 1 individuals, respectively. At week 4 after switching to EVG/COBI/FTC/TDF all patients had HIV-1 RNA <40 copies/mL in both BP and SP. EVG concentrations at the end of the dosing interval (C 24 h ) in BP and SP are summarized in Table 1 . A significant correlation between EVG concentrations in BP and SP samples was observed (Spearman rho 0.952; P < 0.001). The median EVG C 24 h was 277 ng/mL (range 64.8-1790 ng/mL) in BP and 169 ng/mL (range 12.8-792 ng/mL) in SP. In only one individual was the EVG concentration in SP lower than the blood plasma proteinbinding adjusted 95% inhibitory concentration (PA-IC 95 ) for wild-type HIV-1 (45 ng/mL), the pharmacokinetic parameter best associated with its antiviral activity [15] (Fig. 1) . Of note, this individual also had the lowest EVG C 24 h in BP (64.8 ng/mL). Nonetheless, the SP concentration in this subject (12.8 ng/mL) was 23-fold higher than the upper limit of the in vitro unbound EVG concentration producing a 50% effective response (EC 50 ) in HIV-1 clinical isolates (0.04-0.55 ng/mL) [16] . The median SP-to-BP EVG concentration ratio was 0.39 (range 0.20-0.92). The inter-individual variability of EVG concentrations in SP and BP was high, with coefficients of variation of 107% and 105%, respectively, but the inter-individual variability of the SP:BP concentration ratio was lower (coefficient of variation 47%).
Discussion
In this study, the first assessing EVG concentrations in SP in MLWH, we found that, at 4 weeks after switching to EVG/COBI/FTC/TDF, EVG C 24 in BP was higher than the PA-IC 95 (45 ng/mL) [15] in all patients, with a median EVG C 24 6-fold higher than the PA-IC 95 . These results are consistent with findings reported in healthy HIVuninfected volunteers [16] , although the inter-individual variability was higher in our study, probably as a consequence of the lower number of patients that were analysed. EVG C 24 in SP was also higher than the PA-IC 95 in all but one individual, with a median C 24 3.7-fold above this PA-IC 95 , and at least 23-fold the upper end of the in vitro protein-free EVG EC 50 of HIV-1 clinical isolates (0.04-0.55 ng/mL).
EVG is 99.4% bound to plasma proteins, preferentially to albumin over alpha-1-acid glycoprotein [15] . The percentage of EVG protein binding in SP is currently uncertain. It is known, however, that protein patterns in BP and SP differ, with lower albumin and alpha-1-acid glycoprotein concentrations in SP. Hence, protein binding is expected to be lower in SP than in BP, and the fraction of free active EVG in SP presumably higher [17, 18] . Of note, HIV-1 RNA in SP was < 40 copies/mL in all MLWH, CV, coefficient of variation; SD, standard deviation. *Concentrations (ng/mL) in BP and SP 4 weeks after switching to elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF) and at the end of the dosing interval (24 h after the last dose and before the next dose).
which suggests that SP EVG concentrations suffice to maintain HIV suppression in this compartment. However, further studies measuring unbound EVG concentrations in SP would provide better information on EVG activity in this compartment. Drug exposure in the genital tract is mainly conditioned by physical-chemical properties, such as molecular weight, lipophilicity, and the degree of blood plasma protein binding [18] . We found that the EVG SP concentrations represented 39% of paired BP concentrations. Taking into account that EVG is > 99% bound to plasma proteins, EVG seminal exposure was higher than the expected free drug concentration, suggesting that passive diffusion of protein-bound EVG may occur, or, more likely, that drug uptake transporters in addition to passive diffusion of unbound drug may be implicated in EVG penetration in the male genital tract [19] . When compared to other integrase transfer inhibitors, the BP-to-SP penetration rate of EVG is lower than that of raltegravir (325%) [20] , but higher than that of dolutegravir (6.8%) [21] .
In this study, only extracellular EVG concentrations were measured. However, the antiviral activity of EVG is associated with the maintenance of plasma concentrations continually above the IC 95 [16] . In addition, as EVG is an integrase inhibitor with a low dissociative half life, a long intracellular persistence is not expected [22] . Therefore, the assessment of EVG concentrations in mononuclear seminal cells presumably would not have changed substantially our results.
As mentioned above, this study is the first to assess EVG concentrations in the semen of MLWH. However, some limitations should be noted. The small sample size and single EVG determination make the results more susceptible to influence by inter-individual and intraindividual variability. Nevertheless, the sample size is similar to that reported in other studies evaluating ARV concentrations in viral reservoirs. Furthermore, unbound EVG concentrations were not determined. Further studies evaluating EVG seminal protein binding and free concentrations would be of interest to confirm the high EVG seminal concentrations observed in our study.
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